Biomerica to implement 1-for-8 reverse stock split to regain Nasdaq compliance

From GlobeNewswire: 2025-04-16 09:00:00

Biomerica, Inc. (NASDAQ: BMRA) will implement a 1-for-8 reverse stock split of its common stock, effective April 21, 2025, to increase the bid price and regain compliance with Nasdaq listing requirements. Stockholders approved the split at the 2024 Annual Meeting. The split will reduce outstanding shares from 20,366,095 million to 2,545,762 million. The reverse split will occur automatically without additional action from stockholders. Biomerica’s transfer agent, Issuer Direct Corporation, will handle adjustments for stockholders. The company’s common stock will continue to trade on Nasdaq under the symbol “BMRA” and the new CUSIP number will be 09061H406.

Biomerica, Inc. is a global biomedical technology company focusing on gastrointestinal and inflammatory diseases. The company developed the inFoods IBS test, which assesses immunoreactivity to specific foods to help manage IBS symptoms. Clinical results showed statistically significant improvement in abdominal pain intensity for patients on the treatment diet compared to the placebo diet. Biomerica’s products aim to improve health and reduce healthcare costs. The company’s website and SEC filings provide additional information on their products and technologies.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Biomerica’s press release contains forward-looking statements related to the company’s financial position, sales growth, and revenue diversification. Actual results may differ from these statements due to important risks and uncertainties. The company is not obligated to update forward-looking statements after the release date. For more information, contact Corporate Contact Zack Irani at 949-645-2111 or investors@biomerica.com. Source: Biomerica, Inc.



Read more at GlobeNewswire: Biomerica Announces Reverse Stock Split